Agreements Between Parties Clause Samples
Agreements Between Parties. (a) As of the Effective Date, Genentech and Novartis each represent and warrant to Tanox that aside from the agreements listed in Part A of Schedule C, agreements between all three of the Parties and agreements with one or more Third Parties which are related to and entered into solely in the ordinary course of the implementation of development or commercialization activities regarding Anti-IgE Antibodies or Anti-IgE Products pursuant to the Outline of Terms, the Original JCA or the Original D&L Agreement, or which are related to litigation or litigation procedures between the Parties or anticipated litigation with any Third Party, there are no agreements between Genentech and Novartis which remain in effect after the Effective Date relating to the clinical development, manufacture or commercialization (including, without limitation, with respect to the sharing of costs or inter-Party transfers or sales of Anti-IgE Product) of Anti-IgE Antibodies, Anti-IgE Products or other Antibody products which are known to directly or indirectly, operate through or within the IgE pathway to inhibit or otherwise interact with IgE;
(b) As of the Effective Date, Tanox and Novartis each represent and warrant to Genentech that, aside from the agreements listed in Part B of Schedule C, agreements between all three of the Parties and aside from agreements with one or more Third Parties which are related to and entered into solely in the ordinary course of the implementation of development or commercialization activities regarding Anti-IgE Antibodies or Anti-IgE Products pursuant to the Outline of Terms, the Original JCA or the Original D&L Agreement, or which are related to litigation or litigation procedures between the Parties or anticipated litigation with any Third Party, there are no agreements between Tanox and Novartis which remain in effect after the Effective Date relating to the clinical development, manufacture or commercialization (including, without limitation, with respect to the sharing of costs or inter-Party transfers or sales of Anti-IgE Product) of Anti-IgE Antibodies, Anti-IgE Products or other Antibody products which are known to directly or indirectly, operate through or within the IgE pathway to inhibit or otherwise interact with IgE; and
(c) As of the Effective Date, Tanox and Genentech each represent and warrant to Novartis that, aside from the agreements listed in Part C of Schedule C, agreements between all three of the Parties and aside from agreem...
Agreements Between Parties. Any and all existing agreements between Purchasers and Seller, E▇▇▇▇▇ and Seller, and B▇▇▇▇▇▇ and Seller, will be terminated. At closing, E▇▇▇▇▇ and B▇▇▇▇▇▇ shall each enter into Non-Competition, Non-Disclosure and Non-Solicitation Agreements with the Company.
Agreements Between Parties. A. General Provisions
1. The purpose of this Agreement is to promote the timely and orderly completion of the project mandated by the Act with due regard for the public health and safety. Essential to this timely and orderly completion is a relationship between the agenctes marked by open and candid communications at all levels and prompt resolution of any issues which may arise.
2. Insofar as practicable, the NRC agrees to receive and use information and reports developed in the course of the Depart- ' ment's routine operations, and in accordance with Department administrative rules, regulations, procedures and orders which apply to its management and control of the project. The Depart- ment will, however, provide the NRC such additional information as the NRC may require to identify any potential radiological ▇▇▇'ger to the public health and safety which may be presented by the prcject. To the extent not subject to the exemptions contained in 5 USC S 552(b), information or reports required under this agreement to be submitted by the Department to the ; NRC, for review and any comments provided by the NRC to the Department in response thereto, shall be available for public inspection.
3. NRC comments resulting from its review and consultation will be discussed between the respective Project Managers and confirmed in writing. The Department will inform tne NRC in writing of the disposition of such comments upon NRC's request. . , a --g e-y 3 y -- 4 y,y -- w - ep - + - - - g *- -e -e
Agreements Between Parties. A. Business Practices Associated with NRC Work Performed by DOE Laboratories All NRC funded work performed at the DOE laboratories shall be administered in accordance with standard NRC and DOE policies and procedures as agreed to and implemented by each agency. The DOE policies governing work for others are set forth in DOE order 481.1, Work for Others (Non-Department of Energy Funded Work). The NRC policies for work placed at DOE laborctories are set forth in NRC Management Directive 11.7, NRC Procedures for Placement and Monitoring of Work with the U.S. Department of Energy (DOE).
Agreements Between Parties. The terms of sampling recognize the date of sample retrieval from the above subject property to have commenced on [Date] at [Time] The Parties Understand and Voluntarily Agree as follows:
Agreements Between Parties. This Lease contains all of the agreements and understandings of the parties and cannot be amended or modified except by a written agreement.
Agreements Between Parties